Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romiplostim - Amgen

Drug Profile

Romiplostim - Amgen

Alternative Names: AMG-531; Nplate; Romiplate

Latest Information Update: 10 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen
  • Class Antianaemics; Carrier proteins; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Thrombopoietin receptor agonists; Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura
  • Preregistration Aplastic anaemia
  • Phase II Thrombocytopenia
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 19 Dec 2018 Preregistration for Idiopathic thrombocytopenic purpura (In adults) in USA (SC)
  • 19 Dec 2018 Amgen files sBLA for treatment of patients with Idiopathic thrombocytopenic purpura (In adults) in USA
  • 15 Dec 2018 Launched for Idiopathic thrombocytopenic purpura (In adolescents, In children) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top